The Present and Future of Lung Cancer Screening – Self-paced module – IARC-ESMO Cancer Prevention Learning and Capacity-Building Initiative

Current Status

Not Enrolled

Price

Free

Get Started

This resource is now hosted on the IARC Learning space of the new WHO Academy learning platform. Visit the platform here: https://whoacademy.org/partners/IARC/11-iarc-esmo-learning-and-capacity-building-initiative-for-cancer-prevention

Lectures

Questions and answers

Quiz

Certificate of completion

Test your knowledge!

TRUE OR FALSE?

Study design plays an instrumental role when evaluating the clinical utility of lung cancer screening and the added value of new tools, such as biomarkers and artificial intelligence.

Enroll in this course to find out.

WATCH THE VIDEO EXCERPT!

Date of the recording: 6 December 2022

Webinar organized with the support of and in collaboration with the European Society for Medical Oncology (ESMO).

INTRODUCTION BY

Dr Rosa Giuliani

Consultant in Medical Oncology, Clatterbridge Cancer Centre, United Kingdom

Director of Public Policy, European Society for Medical Oncology (ESMO)

About Dr Rosa Giuliani

SPEAKERS

LUNG CANCER SCREENING: WHERE DO WE STAND?

Professor Joachim Aerts

Head, Department of Pulmonary Medicine

Erasmus University Medical Center, Netherlands

There is a lot of debate about the efficacy of lung cancer screening. This presentation will discuss the latest state of affairs of the published data on lung cancer screening

Short biography: Professor Joachim Aerts

Professor Joachim Aerts has been the Head of the Department of Pulmonary Medicine at the Erasmus University Medical Center in Rotterdam, Netherlands, since 2018. His main research focus is on fundamental, translational, and clinical research in immuno-oncology, with a strong focus on lung cancer and mesothelioma. As principal investigator and as co-investigator, Professor Aerts is involved in many studies in both humans and animals.

Professor Aerts is the leader of the core network on mesothelioma and a board member of the European Reference Network on Rare Respiratory Diseases (ERN-Lung) and a member of the board of directors of the International Association for the Study of Lung Cancer (IASLC). He is a frequent invited speaker at international conferences, and he is a scientific committee member of multiple national and international societies, such as NVALT, EORTC, ASCO, ESMO, ETOP, AACR, ERS, and ATS. Professor Aerts is a co-author of more than 200 articles in international peer-reviewed scientific journals.

THE FUTURE OF LUNG CANCER SCREENING: RISK PREDICTION, BIOMARKERS, AND ARTIFICIAL INTELLIGENCE

Dr Hilary Robbins

Scientist, Genomic Epidemiology Branch

International Agency for Research on Cancer, Lyon, France

Lung cancer screening programmes can be made more effective and efficient by using information about individual risk to tailor aspects of eligibility, screening frequency, and nodule follow-up. This presentation will discuss research developments in predicting lung cancer occurrence using statistical models, blood-based biomarkers, and artificial intelligence with low-dose computed tomography (CT) images.

About Dr Hilary Robbins